EE200300281A - Fumaarhappe derivaadid kui NF-kappaB inhibiitorid - Google Patents

Fumaarhappe derivaadid kui NF-kappaB inhibiitorid

Info

Publication number: EE200300281A
Authority: EE; Estonia
Prior art keywords: fumaric acid; acid derivatives; kappab inhibitors; kappab; inhibitors
Prior art date: 2001-01-12

Application number

EEP200300281A

Other languages

English (en)

Inventor

Kumar Joshi Rajendra

Strebel Hans-Peter

Petzelbauer Peter

Original Assignee

Fumapharm Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-12

Filing date

2002-01-08

Publication date

2003-10-15

2002-01-08 Application filed by Fumapharm Ag filed Critical Fumapharm Ag

2003-10-15 Publication of EE200300281A publication Critical patent/EE200300281A/et

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Virology (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Dermatology (AREA)

EEP200300281A 2001-01-12 2002-01-08 Fumaarhappe derivaadid kui NF-kappaB inhibiitorid EE200300281A (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10101307A DE10101307A1 (de)	2001-01-12	2001-01-12	Fumarsäurederivate als NF-kappaB-Inhibitor
PCT/EP2002/000108 WO2002055067A2 (de)	2001-01-12	2002-01-08	Fumarsäurederivate als nf-kappab-inhibitor

Publications (1)

Publication Number	Publication Date
EE200300281A true EE200300281A (et)	2003-10-15

Family

ID=7670424

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200300281A EE200300281A (et)	2001-01-12	2002-01-08	Fumaarhappe derivaadid kui NF-kappaB inhibiitorid

Country Status (22)

Country	Link
US (2)	US20040054001A1 (et)
EP (1)	EP1408947A2 (et)
JP (2)	JP2004528281A (et)
CN (1)	CN1520291A (et)
AU (1)	AU2002244638B2 (et)
BG (1)	BG107829A (et)
BR (1)	BR0206381A (et)
CA (1)	CA2428075A1 (et)
CZ (1)	CZ20031918A3 (et)
DE (1)	DE10101307A1 (et)
EE (1)	EE200300281A (et)
HU (1)	HUP0302650A3 (et)
IL (1)	IL156849A0 (et)
MX (1)	MXPA03006248A (et)
NO (1)	NO20031450L (et)
NZ (1)	NZ525148A (et)
PL (1)	PL363603A1 (et)
RU (1)	RU2282440C2 (et)
SK (1)	SK8252003A3 (et)
WO (2)	WO2002055066A1 (et)
YU (1)	YU55903A (et)
ZA (1)	ZA200305343B (et)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19853487A1 (de) *	1998-11-19	2000-05-25	Fumapharm Ag Muri	Verwendung von Dialkylfumaraten
DE10217314A1 (de) *	2002-04-18	2003-11-13	Fumapharm Ag Muri	Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
ES2297461T3 (es)	2003-09-09	2008-05-01	Fumapharm Ag	Uso de derivados del acido fumarico para tratar la insuficiencia cardiaca y el asma.
DE10360869A1 (de) *	2003-09-09	2005-04-07	Fumapharm Ag	Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma
DE10342423A1 (de) *	2003-09-13	2005-04-14	Heidland, August, Prof. Dr.med. Dr.h.c.	Verwendung von Fumarsäurederivaten zur Prophylaxe und zur Behandlung von Genomschäden
PL2801355T3 (pl) *	2004-10-08	2015-10-30	Fwp Ip Aps	Kompozycje farmaceutycznie o kontrolowanym uwalnianiu zawierające ester kwasu fumarowego
US20070142905A1 (en) *	2005-12-16	2007-06-21	Medtronic Vascular, Inc.	Medical devices to treat or inhibit restenosis
RU2313337C1 (ru) *	2006-05-18	2007-12-27	Государственное учреждение Научный центр медицинской экологии Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук	Лекарственное средство для лечения хронического гепатита в
CN101588803B (zh) *	2006-12-06	2013-03-20	康乃尔研究基金会有限公司	中等持续时间神经肌肉阻断剂及其拮抗剂
EP2680010A1 (en)	2007-02-08	2014-01-01	Biogen Idec MA Inc.	Nrf2 screening assays and related methods and compositions
US20100130607A1 (en) *	2007-02-08	2010-05-27	Ralf Gold	Neuroprotection in demyelinating diseases
KR20090028047A (ko) *	2007-09-13	2009-03-18	경북대학교 산학협력단	디메틸푸마레이트의 신규 용도
DE102008030023A1 (de) *	2008-06-16	2009-12-17	Eberhard-Karls-Universität Tübingen Universitätsklinikum	Arzneimittel zur Behandlung einer durch Parasiten verursachten Krankheit
WO2010022177A2 (en) *	2008-08-19	2010-02-25	Xenoport, Inc.	Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
EP2379063B2 (en)	2009-01-09	2021-02-24	Fwp Ip Aps	Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
WO2010107488A1 (en)	2009-03-17	2010-09-23	Cornell University	Reversible nondepolarizing neuromuscular blockade agents and methods for their use
CA2760133A1 (en) *	2009-04-29	2010-11-04	Biogen Idec Ma Inc.	Treatment of neurodegeneration and neuroinflammation
US9220700B2 (en)	2009-08-19	2015-12-29	Cornell University	Cysteine for physiological injection
SI2718257T1 (en)	2011-06-08	2018-04-30	Biogen Ma Inc.	PROCEDURE FOR PREPARATION OF HIGH QUALITY CRYSTALINIC DIMETHY OF FUMARAT
US9504679B2 (en)	2011-12-19	2016-11-29	Bjoern Colin Kahrs	Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en)	2011-12-19	2013-06-20	Ares Trading S.A.	Pharmaceutical compositions
CN104169261A (zh)	2012-02-07	2014-11-26	什诺波特有限公司	富马酸吗啉代烃基酯化合物、药物组合物和使用方法
CA2882713A1 (en)	2012-08-22	2014-02-27	Xenoport, Inc.	Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US20140056973A1 (en)	2012-08-22	2014-02-27	Xenoport, Inc.	Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug
US20140171504A1 (en) *	2012-12-14	2014-06-19	Georgia Regents Research Institute, Inc.	Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
ES2733961T3 (es)	2012-12-21	2019-12-03	Biogen Ma Inc	Derivados de fumarato sustituidos con deuterio
KR101379427B1 (ko) *	2013-02-13	2014-03-28	경북대학교병원	디메틸푸마레이트를 유효성분으로 포함하는 신섬유증의 예방 또는 치료용 조성물
NZ741985A (en)	2013-03-14	2019-12-20	Alkermes Pharma Ireland Ltd	Prodrugs of fumarates and their use in treating various diseases
US8669281B1 (en)	2013-03-14	2014-03-11	Alkermes Pharma Ireland Limited	Prodrugs of fumarates and their use in treating various diseases
WO2014160633A1 (en)	2013-03-24	2014-10-02	Xenoport, Inc.	Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en)	2013-06-07	2014-12-11	Xenoport, Inc.	Method of making monomethyl fumarate
US9421182B2 (en)	2013-06-21	2016-08-23	Xenoport, Inc.	Cocrystals of dimethyl fumarate
US9416096B2 (en)	2013-09-06	2016-08-16	Xenoport, Inc.	Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use
CN104434904B (zh) *	2013-09-22	2018-09-04	深圳翰宇药业股份有限公司	一种复方微丸胶囊的制备方法及其制备的复方微丸胶囊
EP3656379A1 (en) *	2013-12-12	2020-05-27	Almirall S.A.	Pharmaceutical compositions comprising dimethyl fumarate
EP3079663A1 (en)	2013-12-13	2016-10-19	Biogen MA Inc.	Controlled release dosage form for once daily administration of dimethyl fumarate
TWI572358B (zh) *	2013-12-20	2017-03-01	財團法人生物技術開發中心	α－烯醇化酶特異性抗體及其使用在免疫疾病之方法
US9604922B2 (en)	2014-02-24	2017-03-28	Alkermes Pharma Ireland Limited	Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US10098863B2 (en)	2014-02-28	2018-10-16	Banner Life Sciences Llc	Fumarate esters
WO2015128492A1 (en) *	2014-02-28	2015-09-03	Maghazachi Azzam A	Monomethyl- and dimethylfumarate for nk cell activation
WO2015130998A1 (en)	2014-02-28	2015-09-03	Banner Life Sciences Llc	Controlled release enteric soft capsules of fumarate esters
US9636318B2 (en)	2015-08-31	2017-05-02	Banner Life Sciences Llc	Fumarate ester dosage forms
US9326947B1 (en)	2014-02-28	2016-05-03	Banner Life Sciences Llc	Controlled release fumarate esters
US9999672B2 (en)	2014-03-24	2018-06-19	Xenoport, Inc.	Pharmaceutical compositions of fumaric acid esters
CN104027311A (zh) *	2014-05-09	2014-09-10	万特制药(海南)有限公司	一种含有富马酸二甲酯的肠溶缓释微丸
WO2016061393A1 (en)	2014-10-15	2016-04-21	Xenoport, Inc.	Fumarate compounds, pharmaceutical compositions, and methods of use
WO2016074684A1 (en) *	2014-11-11	2016-05-19	Syddansk Universitet	Fumaric acid derivatives for medical use
MA40982A (fr) *	2014-11-19	2017-09-26	Biogen Ma Inc	Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
CN104523602B (zh) *	2014-12-12	2018-06-05	广东东阳光药业有限公司	一种富马酸二甲酯肠溶微片及其制备方法
CN105797154B (zh) *	2014-12-31	2020-03-10	中国科学院上海生命科学研究院	软骨干细胞的分离及其应用
EP3270911A4 (en) *	2015-03-17	2018-08-29	Hetero Labs Limited	Pharmaceutical compositions of dimethyl fumarate
WO2016205270A1 (en) *	2015-06-17	2016-12-22	Biogen Ma Inc.	Dimethyl fumarate particles and pharmaceutical compositions thereof
US10213411B2 (en)	2015-08-27	2019-02-26	Vijaykumar Rajasekhar	Use of prodrugs of fumarates in treating heart failure diseases
WO2017060400A1 (en)	2015-10-07	2017-04-13	Neurovive Pharmaceutical Ab	Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
DE102015117882A1 (de)	2015-10-21	2017-04-27	Mehrdad Ghashghaeinia	Pharmazeutische Zusammensetzung
US10463642B2 (en)	2016-02-01	2019-11-05	Vijaykumar Rajasekhar	Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate
US20190029987A1 (en) *	2016-02-12	2019-01-31	Universitat Zurich	Dimethyl fumarate (dmf) for prevention or treatment of gout, acne, diabetes, vitiligo and/or pyoderma gangrenosum
CN106265621B (zh) *	2016-09-19	2019-05-17	苏州大学	富马酸二甲酯在制备预防和治疗移植物抗宿主病及移植物抗白血病药物中的应用
JP6866603B2 (ja) *	2016-10-12	2021-04-28	三菱ケミカル株式会社	樹脂組成物、防汚塗料組成物および樹脂組成物の製造方法
CN107088190A (zh) *	2016-11-23	2017-08-25	中南大学湘雅医院	富马酸酯在制备治疗肝病药物中的应用
CN107021996B (zh) *	2017-05-24	2020-02-14	中国海洋大学	一种短肽、其应用以及由其得到的抗菌组合物
CA3059293A1 (en)	2017-06-23	2018-12-27	Almirall, S.A.	Pharmaceutical compositions comprising dimethyl fumarate
WO2020094767A1 (en)	2018-11-08	2020-05-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of nrf2 activators for the treatment of staphylococcus aureus infections
JP7406566B2 (ja)	2019-04-17	2023-12-27	イクシェルファーマエルエルシー	フマル酸モノメチルのプロドラッグ
US11903918B2 (en)	2020-01-10	2024-02-20	Banner Life Sciences Llc	Fumarate ester dosage forms with enhanced gastrointestinal tolerability
WO2022038365A2 (en) *	2020-08-21	2022-02-24	Sitryx Therapeutics Limited	Novel compounds
WO2024047248A1 (en)	2022-09-02	2024-03-07	Institut National de la Santé et de la Recherche Médicale	Use of nrf2 activators for the treatment of cerebral small vessel disease

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2993837A (en) *	1959-07-13	1961-07-25	Frosst & Co Charles E	Enteric coated tablets
FR6808M (et) *	1967-09-22	1969-03-24
US3832287A (en) *	1972-03-02	1974-08-27	Lilly Co Eli	Dipeptide antibiotic and method for the production thereof
DE3127432A1 (de) *	1981-07-11	1983-02-03	Bayer Ag, 5090 Leverkusen	Verfahren zur herstellung von fumarsaeuremonoester
US5149695A (en) *	1985-01-15	1992-09-22	Speiser Peter P	Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same
CH664150A5 (de) *	1985-01-15	1988-02-15	Peter Paul Prof Dr Speiser	Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
JPS61194020A (ja) *	1985-02-22	1986-08-28	Dai Ichi Seiyaku Co Ltd	網膜症治療剤
US5214196A (en) *	1987-09-04	1993-05-25	Dexter Chemical Corporation	Diethyl ester of di-glycyl fumaramide
US5242905A (en) *	1987-09-04	1993-09-07	Dexter Chemical Corporation	Pharmaceutical compositions for the treatment of psoriasis
US4959389A (en) *	1987-10-19	1990-09-25	Speiser Peter P	Pharmaceutical preparation for the treatment of psoriatic arthritis
US5424332A (en) *	1987-10-19	1995-06-13	Speiser; Peter P.	Pharmaceutical composition and process for the production thereof
WO1992012952A1 (en) *	1991-01-18	1992-08-06	Dexter Chemical Corporation	Malic acid derivatives and compositions for the treatment of psoriasis
IT1251166B (it) *	1991-08-09	1995-05-04	Chiesi Farma Spa	Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono
US5763408A (en) *	1992-06-03	1998-06-09	Fuji Photo Film Co., Ltd.	Amino acid derivatives and application thereof
GB2294637B (en) *	1993-06-08	1997-11-12	Raymond K Brown	Therapeutic compositions and methods of use
US5407772A (en) *	1993-11-30	1995-04-18	Xerox Corporation	Unsaturated polyesters
IL110380A0 (en) *	1994-07-20	1994-10-21	Agis Ind 1983 Ltd	Antiviral topical pharmaceutical compositions
US5589504A (en) *	1994-07-26	1996-12-31	Cornell Research Foundation, Inc.	Treatment of newborn jaundice
EP0969869A2 (en) *	1996-07-26	2000-01-12	Susan P. Perrine	Compositions comprising an inducing agent and an anti-viral agent for the treatment of blood, viral and cellular disorders
AU740351B2 (en) *	1996-12-18	2001-11-01	Abbott Gmbh & Co. Kg	Heterocyclic carboxylic acid derivatives, their preparation ans use as endothelin receptor antagonists
WO1998027970A2 (en) *	1996-12-24	1998-07-02	National Research Council Of Canada	Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
US5972363A (en) *	1997-04-11	1999-10-26	Rohm And Haas Company	Use of an encapsulated bioactive composition
DE19721099C2 (de) *	1997-05-20	1999-12-02	Fumapharm Ag Muri	Verwendung von Fumarsäurederivaten
DE19735410A1 (de) *	1997-08-14	1999-02-18	Basf Ag	2-{3-[4-(2-t-Butyl-6-trifluormethylpyrimidin-4-yl)piperazin-1-yl]propylmercapto}pyrimidin-4-ol-fumarat
DE19814358C2 (de) *	1998-03-31	2002-01-17	Fumapharm Ag Muri	Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
DE19839566C2 (de) *	1998-08-31	2002-01-17	Fumapharm Ag Muri	Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19848260C2 (de) *	1998-10-20	2002-01-17	Fumapharm Ag Muri	Fumarsäure-Mikrotabletten
DE19853487A1 (de) *	1998-11-19	2000-05-25	Fumapharm Ag Muri	Verwendung von Dialkylfumaraten
DE10000577A1 (de) *	2000-01-10	2001-07-26	Fumapharm Ag Muri	Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
RU2160589C1 (ru) *	2000-05-18	2000-12-20	Алекс Кашлинский	Средство для снижения алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома и способ снижения алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома с использованием этого средства

2001
- 2001-01-12 DE DE10101307A patent/DE10101307A1/de not_active Withdrawn
- 2001-04-19 WO PCT/EP2001/004454 patent/WO2002055066A1/de not_active Ceased
2002
- 2002-01-08 YU YU55903A patent/YU55903A/sh unknown
- 2002-01-08 RU RU2003124751/15A patent/RU2282440C2/ru active
- 2002-01-08 SK SK825-2003A patent/SK8252003A3/sk not_active Application Discontinuation
- 2002-01-08 NZ NZ525148A patent/NZ525148A/en unknown
- 2002-01-08 EE EEP200300281A patent/EE200300281A/et unknown
- 2002-01-08 WO PCT/EP2002/000108 patent/WO2002055067A2/de not_active Ceased
- 2002-01-08 MX MXPA03006248A patent/MXPA03006248A/es not_active Application Discontinuation
- 2002-01-08 AU AU2002244638A patent/AU2002244638B2/en not_active Ceased
- 2002-01-08 JP JP2002555801A patent/JP2004528281A/ja not_active Withdrawn
- 2002-01-08 US US10/250,983 patent/US20040054001A1/en not_active Abandoned
- 2002-01-08 CA CA002428075A patent/CA2428075A1/en not_active Abandoned
- 2002-01-08 EP EP02712806A patent/EP1408947A2/de not_active Withdrawn
- 2002-01-08 HU HU0302650A patent/HUP0302650A3/hu unknown
- 2002-01-08 PL PL02363603A patent/PL363603A1/xx not_active Application Discontinuation
- 2002-01-08 BR BR0206381-6A patent/BR0206381A/pt not_active IP Right Cessation
- 2002-01-08 CN CNA02803628XA patent/CN1520291A/zh active Pending
- 2002-01-08 CZ CZ20031918A patent/CZ20031918A3/cs unknown
- 2002-01-08 IL IL15684902A patent/IL156849A0/xx unknown
2003
- 2003-03-28 NO NO20031450A patent/NO20031450L/no not_active Application Discontinuation
- 2003-05-20 BG BG107829A patent/BG107829A/bg unknown
- 2003-07-10 ZA ZA200305343A patent/ZA200305343B/en unknown
2007
- 2007-08-02 US US11/833,150 patent/US20080233185A1/en not_active Abandoned
2008
- 2008-11-13 JP JP2008290821A patent/JP2009073854A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
AU2002244638B2 (en)	2005-05-05
CA2428075A1 (en)	2002-07-18
HUP0302650A3 (en)	2009-08-28
YU55903A (sh)	2006-08-17
US20040054001A1 (en)	2004-03-18
PL363603A1 (en)	2004-11-29
NO20031450D0 (no)	2003-03-28
MXPA03006248A (es)	2004-04-02
WO2002055067A3 (de)	2004-02-26
BG107829A (bg)	2004-12-30
JP2009073854A (ja)	2009-04-09
EP1408947A2 (de)	2004-04-21
HUP0302650A2 (hu)	2003-11-28
JP2004528281A (ja)	2004-09-16
NO20031450L (no)	2003-09-12
WO2002055066A1 (de)	2002-07-18
SK8252003A3 (en)	2003-12-02
RU2282440C2 (ru)	2006-08-27
BR0206381A (pt)	2004-08-03
ZA200305343B (en)	2004-08-17
US20080233185A1 (en)	2008-09-25
CZ20031918A3 (en)	2004-04-14
NZ525148A (en)	2006-06-30
IL156849A0 (en)	2004-02-08
CN1520291A (zh)	2004-08-11
RU2003124751A (ru)	2005-01-10
DE10101307A1 (de)	2002-08-01
WO2002055067A2 (de)	2002-07-18

Publication	Publication Date	Title
EE200300281A (et)	2003-10-15	Fumaarhappe derivaadid kui NF-kappaB inhibiitorid
AU2002244638A1 (en)	2003-02-06	Fumaric acid derivatives as NF-kappaB inhibitors
EE200200140A (et)	2003-04-15	Pteridinoonid kui kinaasi inhibiitorid
CY2016042I2 (el)	2017-03-15	Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
NO20034044D0 (no)	2003-09-12	Metallproteinase-inhibitorer
EE200300384A (et)	2003-12-15	Kinasoliinid kui MMP-13 inhibiitorid
ATE524441T1 (de)	2011-09-15	Vla-4-inhibitoren
EE05432B1 (et)	2011-06-15	Prroloprimidiinid kui valgukinaasi inhibiitorid
DE60211317D1 (de)	2006-06-14	Rho-kinase inhibitoren
DE60218138D1 (de)	2007-03-29	Rho-kinase inhibitoren
IS7138A (is)	2004-01-30	Alkýn-arýl fosfódíesterasa-4 hindrar
DE60234125D1 (de)	2009-12-03	E inhibitoren
EE200100509A (et)	2002-12-16	Aminopürimidiinid kui sorbitooldehüdrogenaasi inhibiitorid
PL376957A1 (pl)	2006-01-09	Pochodne 2-pirydonu jako inhibitory elastazy neutrofili
EE200100368A (et)	2003-04-15	w-karboksüarüülasendatud difenüülkarbamiidid kui raf-kinaasi inhibiitorid
EE200100486A (et)	2003-02-17	Amiinderivaadid proteaasi inhibiitoritena
NO20034032D0 (no)	2003-09-11	Metallproteinase-inhibitorer
IS7509A (is)	2004-10-15	Þíoxantínafleiður sem mergperoxídasatálmar
NO20050665L (no)	2005-04-18	Pyrrolidonderivater som MAOE inhibitoere
EE200300266A (et)	2003-10-15	Asendatud 8-arüülkinoliinid kui fosfodiesteraas-4inhibiitorid
IL150806A0 (en)	2003-02-12	Piperidine-and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
HUP0401641A3 (en)	2007-02-28	Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors
DE60009260D1 (de)	2004-04-29	Thiopyranderivate as mmp-inhibitoren
DE60316425D1 (de)	2007-10-31	NF-kappaB-INHIBITOREN
AU2003232362A8 (en)	2003-12-22	4-pyrazol-phenylalanine derivatives as ace-nep inhibitors

Legal Events

Date	Code	Title	Description
2004-04-15	HE1A	Change of address